The Elton Laboratory for Molecular Neuroendocrinology, Department of Human Molecular Genetics and Biochemistry, Faculty of Medicine, Sagol School of Neuroscience and Adams Super Center for Brain Studies, Tel Aviv University, Tel Aviv, 6997801, Israel.
Psychiatric Division, Ben Gurion University of the Negev, Beersheba, Israel.
J Mol Neurosci. 2024 Jan 29;74(1):15. doi: 10.1007/s12031-024-02189-4.
Activity-dependent neuroprotective protein (ADNP) is essential for neurodevelopment and de novo mutations in ADNP cause the ADNP syndrome. From brain pathologies point of view, tauopathy has been demonstrated at a young age, implying stunted development coupled with early/accelerated neurodegeneration. Given potential genotype-phenotype differences and age-dependency, we have assessed here a cohort of 15 individuals (1-27-year-old), using 1-3 longitudinal parent (caretaker) interview/s (Vineland 3 questionnaire) over several years. Our results indicated developmental delays, or even developmental arrests, coupled with potential spurts of development at early ages. Severe outcomes correlated with the truncating high impact mutation, in other words, the remaining mutated protein length as well as with the tested individual age, corroborating the hypothesis of developmental delays coupled with accelerated aging. A significant correlation was noted between mutated protein length and communication, implying a high impact of ADNP on communicative skills. Additionally, correlations were discovered between the two previously described epi-genetic signatures in ADNP emphasizing aberrant acquisition of motor behaviors, with truncating mutations around the nuclear localization signal being mostly affected. Finally, all individuals seem to acquire an age equivalent of 1-6 years, requiring disease modification treatment, such as the ADNP-derived drug candidate, NAP (davunetide), which has recently shown efficacy in women suffering from the neurodegenerative disorder, progressive supranuclear palsy (PSP), a late-onset tauopathy.
活性依赖神经保护蛋白(ADNP)对神经发育至关重要,ADNP 中的新突变会导致 ADNP 综合征。从脑病理学的角度来看,在年轻时就已经证明存在 tau 病,这意味着发育迟缓,伴有早期/加速的神经退行性变。鉴于潜在的基因型-表型差异和年龄依赖性,我们在此评估了 15 名个体(1-27 岁)的队列,使用 1-3 个纵向家长(照顾者)访谈/(Vineland 3 问卷)在几年内进行多次。我们的结果表明存在发育迟缓,甚至发育停滞,伴有早期潜在的发育突增。严重的结果与截断的高影响突变相关,换句话说,剩余突变蛋白的长度以及受测试个体的年龄相关,证实了发育迟缓与加速衰老相结合的假说。在 ADNP 中还发现了突变蛋白长度与沟通之间存在显著相关性,这表明 ADNP 对沟通技能有重大影响。此外,还发现了 ADNP 中先前描述的两个表观遗传特征之间存在相关性,强调了运动行为的异常获得,受核定位信号周围截断突变的影响最大。最后,所有个体似乎都获得了 1-6 岁的年龄当量,需要进行疾病修饰治疗,例如 ADNP 衍生的药物候选物 NAP(davunetide),它最近在患有神经退行性疾病进行性核上性麻痹(PSP)的女性中显示出疗效,这是一种迟发性 tau 病。